BoC Interest Rate Decision (Jan.) The Bank of Canada cut its key interest rate by 50 basis points to 3.25%. The Bank Rate is ...

William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.

To subscribe to Barron's, visit http://www.barrons.com/subscribe January 24, 2025 21:45 ET (02:45 GMT) ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $170.67 which represents a slight increase of $1.47 or 0.87% from the prior close of $169.2. The stock opened at $170.46 and touched a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...

Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...

It raises hope for a fundamental cure for the neurodegenerative condition that affects about 7 million patients worldwide.” A study published in Jama Network Open in December indicated a direct ...

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.

AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular ...